Pathogen Inactivation in Cellular Blood Components: Clinical Trials and Implications of Introduction to Transfusion Medicine
- 1 August 2002
- journal article
- review article
- Published by Wiley in Vox Sanguinis
- Vol. 83, 271-275
- https://doi.org/10.1111/j.1423-0410.2002.tb05316.x
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Prevention of transfusion-associated graft-versus-host disease by inactivation of T cells in platelet componentsSeminars in Hematology, 2001
- Inactivation of cytomegalovirus in platelet concentrates using helinx™ technologySeminars in Hematology, 2001
- Design of clinical trials to evaluate the efficacy of platelet transfusion: The euroSPRITE trial for components treated with helinx™ technologySeminars in Hematology, 2001
- Bacterial contamination of platelet concentrates: Incidence, significance, and preventionSeminars in Hematology, 2001
- Fundamentals of the psoralen-based Helinx™ technology for inactivation of infectious pathogens and leukocytes in platelets and plasmaSeminars in Hematology, 2001
- Functional Characteristics of S‐59 Photochemically Treated Platelet Concentrates Derived from Buffy CoatsVox Sanguinis, 2000
- Corrected count increment and percent platelet recovery as measures of posttransfusion platelet response: problems and a solutionTransfusion, 1999
- Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A lightTransfusion, 1999
- Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates: Current research perspectivesTransfusion Medicine Reviews, 1999
- Implications of transfusion of "undercollected" unitsTransfusion, 1985